Company research
Lipocine Inc.
CIK 1535955Updated Sep 24, 2026
SecurityLPCN · NASDAQ · equity
Name history
MARATHON BAR CORP · through Jul 9, 2013
LPCN price & chart
Loading TradingView…
NASDAQ:LPCN on TradingView ↗In the news
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) News provided by Lipocine Inc. Jan 20, 2026, 08:00 ET Share this article Share to X Share this article Share to X SALT LAKE CITY , Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: ↗
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) News provided by Lipocine Inc. Jan 12, 2026, 08:00 ET Share this article Share to X Share this article Share to X Company on track to report topline results early in t ↗
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01
Other Events
Items 8.01, 9.01
8-K/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 17,005,612Source | 22,510,501Source | 23,001,072Source | 37,542,922Source |
| Property, Plant and Equipment, NetUSD | 104,293Source | 165,075Source | 116,095Source | 131,589Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,205,842Source | 6,205,926Source | 4,771,758Source | 3,148,496Source |
| Assets, CurrentUSD | 16,877,566Source | 22,321,673Source | 22,861,224Source | 34,135,080Source |
| Prepaid Expense and Other Assets, CurrentUSD | 787,600Source | 567,915Source | 773,424Source | 945,319Source |
| Other Assets, NoncurrentUSD | 23,753Source | 23,753Source | 23,753Source | 23,753Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,528,196Source | 1,512,936Source | 2,631,629Source | 1,907,982Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 8,944Source | 8,863Source | 8,860Source | 8,852Source |
| Additional Paid in CapitalUSD | 223,901,106Source | 220,789,138Source | 220,171,250Source | 219,112,164Source |
| Retained Earnings (Accumulated Deficit)USD | -209,396,367Source | -199,768,862Source | -199,777,214Source | -183,425,043Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,445Source | 9,138Source | 7,259Source | -20,321Source |
| Stockholders' Equity Attributable to ParentUSD | 14,477,416Source | 20,997,565Source | 20,369,443Source | 35,634,940Source |
| Liabilities and EquityUSD | 17,005,612Source | 22,510,501Source | 23,001,072Source | 37,542,922Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,528,196Source | 1,512,936Source | 2,631,629Source | 1,678,126Source |
| Accounts Payable, CurrentUSD | 971,822Source | 271,696Source | 1,395,977Source | 600,388Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,236,374Source | 921,240Source | 1,218,486Source | 1,077,738Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 14,900,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 6,219Source | — | 7,227Source | 9,052Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 242,497Source | 408,551Source | 654,438Source | 636,140Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 700,126Source | -1,124,281Source | 795,589Source | -688,954Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,760,721Source | -1,221,233Source | -11,865,991Source | -11,968,819Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 5,891,085Source | 2,446,061Source | 13,084,686Source | 14,293,707Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 90,086Source | 13,167Source | 133,831Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,869,552Source | 209,340Source | 404,567Source | -2,126,944Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,000,084Source | 1,434,168Source | 1,623,262Source | 197,944Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 21,256Source |
| Income Taxes Paid, NetUSD | 200Source | 681Source | 225Source | 200Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 5,842Source |
| Share-based Payment Arrangement, ExpenseUSD | 242,497Source | 408,551Source | 654,438Source | 636,140Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 14,900,000Source | — | — | — |
| Debt and Equity Securities, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | 61,000Source | 41,000Source | 29,000Source | 9,500Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 250,000Source |
| General and Administrative ExpenseUSD | 3,764,137Source | 5,001,426Source | 4,904,888Source | 4,062,487Source |
| Income Tax Expense (Benefit)USD | 200Source | 681Source | 755Source | 681Source |
| Investment Income, InterestUSD | 744,074Source | 1,146,902Source | 1,366,940Source | 572,578Source |
| Net Income (Loss) Attributable to ParentUSD | -9,627,505Source | 8,352Source | -16,352,082Source | -10,758,636Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | 8,352Source | -16,352,171Source | — |
| Nonoperating Income (Expense)USD | 744,074Source | 1,164,068Source | 1,579,630Source | — |
| Operating ExpensesUSD | 12,348,056Source | 12,353,179Source | 15,080,139Source | 12,619,375Source |
| Operating Lease, ExpenseUSD | 376,000Source | 366,000Source | 355,000Source | 341,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 1,361,420Source |
| Proceeds from Issuance of Common StockUSD | 2,869,552Source | 209,340Source | 404,567Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 211,423Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | 17,166Source | 212,690Source | 565,940Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 500,000Source |
| Operating Income (Loss)USD | -10,371,379Source | -1,155,035Source | -17,930,957Source | -12,119,375Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 1,361,420Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -9,627,305Source | 9,033Source | -16,351,327Source | -10,757,955Source |
| Income Tax Expense (Benefit)USD | 200Source | 681Source | 755Source | 681Source |
| Net Income (Loss) Attributable to ParentUSD | -9,627,505Source | 8,352Source | -16,352,082Source | -10,758,636Source |
| Earnings Per Share, BasicUSD per share | -1.77Source | — | -3.1Source | -0.12Source |
| Earnings Per Share, DilutedUSD per share | -1.69Source | — | -3.14Source | -0.13Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 5,448,871Source | 5,338,957Source | 5,269,671Source | 88,457,243Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 5,708,238Source | 5,422,604Source | 5,269,671Source | 88,875,946Source |
| Additional Financial Items | ||||
| Debt and Equity Securities, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 60,782Source | 41,106Source | 28,661Source | 9,453Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 250,000Source |
| General and Administrative ExpenseUSD | 3,764,137Source | 5,001,426Source | 4,904,888Source | 4,062,487Source |
| Interest ExpenseUSD | — | — | — | 27,098Source |
| Investment Income, InterestUSD | 744,074Source | 1,146,902Source | 1,366,940Source | 572,578Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | 8,352Source | -16,352,171Source | — |
| Nonoperating Income (Expense)USD | 744,074Source | 1,164,068Source | 1,579,630Source | — |
| Operating ExpensesUSD | 12,348,056Source | 12,353,179Source | 15,080,139Source | 12,619,375Source |
| Operating Lease, ExpenseUSD | 376,000Source | 366,000Source | 355,000Source | 341,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 89Source | — |
| Research and Development ExpenseUSD | 8,583,919Source | 7,351,753Source | 10,175,251Source | 8,556,888Source |
Filing attachments
ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, September 14, 2026 - Lipoc…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference SALT LAKE CITY, September 10, 2026 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026. Presentati…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 SALT LAKE CITY, August 4, 2026 - Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) On April…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-03
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Lipocine Inc. Lipocine Appoints Michael J. Grissinger to Board of Directors SALT LAKE CITY, August 3, 2026 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026. “We are pleased to welcome Mike Grissinger to our Board of Directors,…
Read attachment ↗